Dagogo-Jack S, et al. - Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin were investigated. This placebo-controlled randomized study revealed that ertugliflozin added to metformin and sitagliptin was well-tolerated. It provided clinically meaningful, durable glycaemic control, body weight (BW) and systolic blood pressure (SBP) reductions compared to placebo over 52 weeks.